| Nanocarriers and nanoparticles for skin care and dermatological treatments S Gupta, R Bansal, S Gupta, N Jindal, A Jindal Indian dermatology online journal 4 (4), 267-272, 2013 | 209 | 2013 |
| Uncertainty-informed deep learning models enable high-confidence predictions for digital histopathology JM Dolezal, A Srisuwananukorn, D Karpeyev, S Ramesh, S Kochanny, ... Nature communications 13 (1), 6572, 2022 | 93 | 2022 |
| Extramedullary disease in multiple myeloma R Bansal, S Rakshit, S Kumar Blood cancer journal 11 (9), 161, 2021 | 85 | 2021 |
| The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma K Rejeski, DK Hansen, R Bansal, P Sesques, S Ailawadhi, JM Logue, ... Journal of Hematology & Oncology 16 (1), 88, 2023 | 56 | 2023 |
| Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma? O Saifi, WG Breen, SC Lester, WG Rule, B Stish, A Rosenthal, J Munoz, ... Radiotherapy and Oncology 166, 171-179, 2022 | 49 | 2022 |
| Ethical challenges with multiple myeloma BCMA chimeric antigen receptor T cell slot allocation: a multi-institution experience T Kourelis, R Bansal, J Berdeja, D Siegel, K Patel, S Mailankody, M Htut, ... Transplantation and cellular therapy 29 (4), 255-258, 2023 | 37 | 2023 |
| Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma HB Alkhateeb, R Mohty, P Greipp, R Bansal, M Hathcock, A Rosenthal, ... Blood cancer journal 12 (7), 113, 2022 | 32 | 2022 |
| Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT WG Breen, MA Hathcock, JR Young, RO Kowalchuk, R Bansal, ... Journal of hematology & oncology 15 (1), 36, 2022 | 31 | 2022 |
| The impact of granulocyte colony stimulating factor on patients receiving chimeric antigen receptor T-cell therapy JN Barreto, R Bansal, MA Hathcock, CJ Doleski, JR Hayne, TA Truong, ... American journal of hematology 96 (10), E399-E402, 2021 | 22 | 2021 |
| Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions A Major, J Yu, N Shukla, Y Che, TG Karrison, R Treitman, MK Kamdar, ... Blood advances 7 (16), 4528-4538, 2023 | 20 | 2023 |
| Don't put the CART before the horse: The role of radiation therapy in peri-CAR T-cell therapy for aggressive B-cell non-Hodgkin lymphoma O Saifi, WG Breen, SC Lester, WG Rule, BJ Stish, A Rosenthal, J Munoz, ... International Journal of Radiation Oncology* Biology* Physics 116 (5), 999-1007, 2023 | 17 | 2023 |
| Response to COVID-19 vaccination post-CAR T therapy in patients with non-Hodgkin lymphoma and multiple myeloma JE Wiedmeier-Nutor, M Iqbal, AC Rosenthal, ED Bezerra, ... Clinical Lymphoma Myeloma and Leukemia 23 (6), 456-462, 2023 | 17 | 2023 |
| The impact of obesity and body weight on the outcome of patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel K Wudhikarn, R Bansal, A Khurana, MA Hathcock, NN Bennani, J Paludo, ... Blood cancer journal 11 (7), 124, 2021 | 17 | 2021 |
| Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality K Rejeski, Y Wang, DK Hansen, G Iacoboni, E Bachy, R Bansal, ... Blood Advances 8 (8), 1857-1868, 2024 | 16 | 2024 |
| Incidence and risk factors for acute kidney injury after chimeric antigen receptor T-cell therapy N Farooqui, JPT Sy-Go, J Miao, R Mehta, LE Vaughan, NN Bennani, ... Mayo Clinic Proceedings 97 (7), 1294-1304, 2022 | 16 | 2022 |
| Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma R Bansal, M Baksh, JT Larsen, MA Hathcock, D Dingli, AK Stewart, ... Blood cancer journal 13 (1), 47, 2023 | 14 | 2023 |
| The CAR-hematotox score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma K Rejeski, DK Hansen, R Bansal, P Sesques, S Ailawadhi, JM Logue, ... Blood 140 (Supplement 1), 7506-7508, 2022 | 14 | 2022 |
| Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief report A Desai, S Rakshit, R Bansal, Y Ashara, A Potter, R Manochakian, Y Lou, ... Cancer Treatment and Research Communications 36, 100743, 2023 | 13 | 2023 |
| Ethical challenges with CAR T slot allocation with idecabtagene vicleucel manufacturing access. T Kourelis, R Bansal, KK Patel, JG Berdeja, NS Raje, M Alsina, AD Cohen, ... Journal of Clinical Oncology 40 (16_suppl), e20021-e20021, 2022 | 13 | 2022 |
| A population‐based study of outcomes in polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the United States from 2001 to 2015: Comparison with data … CJ Smith, JW Thomas, G Ruan, MC Hyun, R Bansal, N McLaughlin, ... American journal of hematology 96 (12), E464-E468, 2021 | 13 | 2021 |
Yi LinMayo Clinic在 mayo.edu 的电子邮件经过验证
